Key result
GLP-1 therapies show promise for lowering blood pressure in obese patients with resistant hypertension.
Why the study?
Many patients with resistant hypertension struggle to achieve blood pressure control, and no trials have directly evaluated the effect of GLP-1 RAs or dual GLP-1/GIP receptor agonists on resistant hypertension management.
Do GLP-1-based therapies improve blood pressure control and reduce cardiovascular risk in individuals with overweight or obesity who have resistant hypertension?
Do GLP-1-based therapies improve blood pressure control and reduce cardiovascular risk in individuals with overweight or obesity who have resistant hypertension?
GLP-1-based therapies may offer a holistic and effective pharmacological approach to treating resistant hypertension in overweight and obese individuals by simultaneously promoting weight loss, lowering blood pressure, and reducing treatment burden.
Hypothesis-generating for resistant hypertension; dedicated RCTs needed before clinical adoption.
Despite the availability of a wide range of antihypertensive agents, a significant proportion of individuals with resistant hypertension (RHTN) struggle to achieve blood pressure (BP) control. Obesity ranks among the most significant modifiable risk factors for RHTN, with 56-91% of patients with RHTN classified as overweight or obese. Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) are a class of anti-obesity medications that have recently demonstrated efficacy in reducing BP and improving cardiovascular (CV) outcomes in individuals with overweight or obesity. Among the available GLP-1-based therapies, liraglutide, semaglutide, and tirzepatide have been approved for chronic weight management in this population. Tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has the greatest effect on weight loss and BP reduction compared to GLP-1 RAs alone. To our knowledge, no trials have directly evaluated the effect of GLP-1 RAs or dual GLP-1/GIP receptor agonists on RHTN management. In this review article, we propose that targeting weight loss through GLP-1-based therapies should be explored as a treatment option for individuals with RHTN who are overweight or obese.
No takes yet. Share an insight, caveat, or question.
Jarade et al. (2024) conducted a review in Resistant hypertension in individuals with overweight or obesity. GLP-1-based therapies was evaluated. GLP-1-based therapies present a promising pharmacological treatment option for reducing blood pressure and improving cardiovascular outcomes in individuals with resistant hypertension who are overweight or obese.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: